SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: shasta23 who wrote (21851)6/4/1998 5:20:00 PM
From: tonyt  Read Replies (1) of 32384
 
The report also reminds us that "final FDA approval of ONTAK will trigger a $40 million payment by Ligand to Seragen." and that they only have a 12-18 month target price of $20 per share (is this all that we can hope for out of LGND in 12-18 months?).

Also, Legg Manson (;-)) adds a risk rating to their rec's. While others like to state that Buy is their highest rating, it should be noted that Speculative is also their highest risk rating:
Investment Rating: B-Buy, O-Outperform, M-Market Performance, U-Underperform
Risk Rating: 1-Low, 2-Average, 3-Above-Average, 4-Speculative
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News